Skip to main content

Table 6 Summary of active clinical trials applying vaccinal and oncolytic virus strategies

From: Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma

NCT number Agent/Drug Vaccine type Combination drug/s Phase Mechanism Primary outcome Status
NCT02950766 NeoVax Peptide-based Ipilimumab I Personalised neoantigen vaccine Safety, dose Recruiting
NCT03715985 EVAX-01-CAF09b Peptide-based anti-PD-1, anti-PD-L1 I Safety, efficacy Recruiting
NCT00458536 DC tumour fusion Dendritic cell GM-CSF I/II Improving antigen presentation Safety Active not recruiting
NCT03548467 VB10.NEO DNA Plasmid Bempegaldesleukin I/II Improved immune response elicited by CD4+ and CD8+ T cells Safety Recruiting
NCT03633110 GEN-009 Autologous Nivolumab/Pembrolizumab I/II Elicit CD8+ T cell response Safety Active not recruiting
NCT03294083 Pexa-Vec Oncolytic vaccinia virus REGN2819 I Stimulate immune response, replicates in and lyses tumour cells ORR, safety, dose Recruiting